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1. Introduction  
   Migration of medial vascular smooth muscle cells (VSMCs) into the intima, together 
with the targeting mobilization and differentiation into VSMCs of bone marrow-derived 
vascular progenitor cells, is a crucial step that gives rise to the formation of vascular 
proliferative lesions including atheroma and post-angioplasty restenosis.1,2 The control of 
vascular cell motility may confer a useful means to treat vascular proliferative lesions. 
Sphingosine-1-phosphate (S1P) is a recently established lipid mediator that exerts 
pleiotropic effects on diverse cell types including vascular smooth muscle cells (VSMCs) 
and vascular endothelial cells.3-6 These include regulation of cell migration, cell shape and 
cell to cell adhesion, and stimulation of mitogenesis, most of which are mediated via 
S1P-specific G protein-coupled receptor (GPCR) family, including S1P1 receptor (S1P1R), 
S1P2R, and S1P3R.3-6 S1P exhibits unique bimodal activities as an extracellular regulator on 
cell motility. It stimulates or inhibits cell migration, in a manner apparently dependent on 
cell types7; S1P stimulates migration of vascular endothelial cells6 whereas S1P inhibits 
migration of VSMCs.8 We previously demonstrtaed that this bimodal regulation by S1P is 






stimulatory or inhibitory regulation for cell migration.9 Thus, S1P1R and S1P3R act as 
attractant receptors to mediate migration directed toward S1P, whereas S1P2R acts as a 
repellant receptor to mediate inhibition of chemotaxis toward a chemoattractant. 
   Rho family small GTPases, primarily Rac, Cdc42, and Rho, are well-known regulators 
of actin reorganization and myosin motor function and thereby of cell motility.10 We 
observed that platelet-derived growth factor (PDGF) stimulates Rac, but not Cdc42 or Rho 
in VSMCs and that Rac plays an essential role in PDGF-directed chemotaxis.8 We found in 
heterologous expression of each S1P receptor subtype that the attractant receptors S1P1R and 
S1P3R mediate stimulation of Rac whereas the repellant receptor S1P2R inhibits 
chemoattractant-induced Rac activation.9 Thus, S1PRs exert bimodal regulation on cell 
migration primarily through positively or negatively regulating cellular Rac activity. In 
VSMCs, S1P induced inhibition of PDGF-triggered Rac activation as well as migration.8 
  Pleiotropic actions of GPCRs are mediated primarily by four classes of heterotrimeric G 
proteins, Gs, Gi, Gq and G12/13. Several GPCRs including prostaglandin E2 (PGE2) receptors, 
dopamine receptors and adrenomedullin receptors mediate inhibition of motility of VSMCs. 






upon PGE2 receptor stimulation, cyclic AMP mediated Rac inhibition as a mechanism for 
inhibition of VSMC migration.11 Different from these receptors, S1P2R is not a Gs-coupled 
type of receptor.12,13 It is unknown which class of heterotrimeric G protein mediates 
S1P-induced inhibition of VSMC migration. Also, signaling mechanisms downstream of a 
heterotrimeric G protein for inhibition of Rac and migration in VSMCs are not fully defined. 
In the present study, we show in VSMCs that S1P2R induces Rho activation via both the Gq 
and G12/13 classes, which in turn mediates inhibition of Rac and chemotaxis in a manner 
dependent on Rho but independent of Rho kinase. 
 
 
2. Methods  
2.1. Materials 
   S1P and human PDGF-B chain were purchased from BIOMOL (Plymouth Meeting, 
PA, U.S.A.) and Peprotech (London, U.K.), respectively. A mouse monoclonal 
anti-Rac1 antibody (23A8) and rabbit polyclonal anti-phospho (Thr850)-MYPT1 






Mouse monoclonal anti-RhoA antibody (26C4) was from Santa Cruz Biotechnology 
(Santa Cruz, CA, U.S.A.). Rabbit polyclonal anti-MYPT1 antibody (PRB-457C) was 
bought from Covance (Berkley, CA, USA). Mouse monoclonal anti-myc antibody 
(9E10) was obtained from ATCC (Rockville, MA, U.S.A.). JTE-013 and HA-1077 were 
kind gifts from Japan Tabacco (Takatsuki, Japan) and Asahi Chemical Industry (Fuji, 
Japan), respectively. U73122 and BAPTA-AM were purchased from Merck-Calbiochem 
Biosciences (Darmstadt, Germany), and phorbol 12,13-dibutyrate (PDBu) and G418 
were obtained from Sigma (St. Louis, MI, U.S.A.). Pertussis toxin was bought from List 
Biological Laboratories (Campbell, CA, U.S.A.). Botulinum C3 toxin, human PAK1 
(amino acids 75 to 131(CRIB-domain)) and mouse Rhotekin (amino acids 7 to 89 
(Rho-binding domain)) that were fused to glutathione-s-Sepharose (GST) (GST-C3, 
GST-PAK1 and GST-Rhotekin, respectively) were prepared as described previously.28 
 
2.2.Plasmids and adenoviruses 
   The mammalian expression plasmid for S1P2, pME18S-S1P2, was described 






mouse genomic DNA by PCR was ligated onto pME18S at BstXI site. The fusion 
receptor AT1-Gα12, in which the full length Gα12 is fused to the C-terminus of AT1a, was 
generated by the PCR-based method as described previously.13 Replication-deficient 
adenoviruses carrying myc-tagged Gα12-CT, Gα13-CT, Gαq-CT and Gαs–CT were 
described previously.13 The adenovirus encoding β-galactosidase (LacZ) were kindly 
donated by I. Saito (Institute of Medical Sciences, University of Tokyo). The cells were 
infected with adenoviruses at a multiplicity of 200 by incubating VSMCs with an 
adenovirus-containing medium for 1 h, which conferred successful gene transduction in 
nearly 100% of cells without significant cell damage.8,14 After recovery in a fetal calf 
serum (FCS)-containing growth medium for 24 h, the cells were subjected to migration 
assay, or serum-deprived before each experiment.  
 
2.3.Cells 
   Rat aortic VSMCs were isolated by the explant method from an 8-week old Wistar 
male rat, as described previously.8 The present investigation using experimental animals 






US National Institutes of Health (NIH Publication No. 85-23, revised 1996). VSMCs 
were grown in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% 
FCS (Equitech-Bio, Ingram, TX, U.S.A.), 100U/ml of penicillin, and 100 μg/ml of 
streptomycin (Wako, Osaka, Japan). When indicated, VSMCs were pretreated with C3 
toxin (10 μg/ml) in serum-free DMEM for 72 h.13 The VSMCs stably overexpressing 
either AT1 or AT1-Gα12 were established by co-transfecting VSMCs with one of the 
above expression plasmids and pKM3 vector that confers G418 resistance, and selecting 
in the presence of 0.2 mg/ml of G418 as described previously.14 The stable VSMC 
transfectants were maintained in the presence of the same concentration of G418. 
VSMCs were treated with 10 ng/ml pertussis toxin for 24 h when indicated. Total RNA 
was isolated from VSMCs and analyzed for mRNA expression by Northern blotting 
using 32P-labelld cDNA probe as described peviously.8,14 
 
2.4.Transwell migration assay 
   Transwell migration of VSMCs was determined in a modified Boyden chamber 






described in detail previously.8,9 VSMCs (1×105) in 200 μl of serum-free DMEM 
containing 0.1% fatty acid-free bovine serum albumin were loaded into the upper wells, 
whereas the lower wells were filled with the same medium containing various 
concentrations of S1P, angiotensin II, and/or PDGF. The cells were allowed to migrate 
across the porous filter for 5 h at 37°C in a tissue culture incubator. After staining with 
Diff-Quick (Sysmex, Kobe, Japan) and scraping the upper surface of the filter, the 
number of cells that migrated to the lower side of the filter was determined by 
measuring optical densities at 595 nm using a 96-well microplate reader Model 3550 
(Bio-Rad, Hercules, CA). There was a linear positive relationship between an optical 
density (OD) value and a counted number of migrated cells through pores in a range of 
less than 0.2 of OD value.9 In the experiment to examine the effect of the expression of 
a dominant negative form of Rho kinase (DN-ROCK)15 on transwell migration, VSMCs 
were co-transfected with the β-galactosidase expression vector (pCAGGS-LacZ) and 
either the DN-ROCK expression vector pME18S-DN-ROCK or the empty vector as 
described.9 The filter was subjected to staining with 






attached onto the lower side of the filters were counted under a microscope.9 
 
2.5.Determination of the activities of Rho and Rac 
   Pull-down assays to determine GTP-bound active forms of RhoA and Rac1 were 
performed as described in detail previously.8,9,13  Briefly, cells that had been 
serum-deprived for 72 h were stimulated and cell lysates were prepared as described. 
Cell extracts were incubated with the GST-rhotekin (for determination of Rho activity) 
or the GST-PAK1 (for determination of Rac activity) that were immobilized onto 
glutathione-s-Sepharose 4B beads (GE Healthcare, Buckinghamshire, U.K.) at 4°C for 
45 min, followed by three washes. Bound Rho and Rac proteins were detected by 
Western blotting using specific monoclonal antibodies against RhoA and Rac1 and 
quantitated by densitometry, as described. 1/100 of total RhoA and Rac1 present in the 
cell lysate of each sample were also shown in each figure. The amounts of GTP-bound 
active RhoA and Rac1 were normalized for the total amounts of RhoA and Rac1, 
respectively, and expressed as multiples of the value of non-treated control cells, which 








   All data are shown as mean ± SEM and are representative of at least three 
independent experiments with similar results. ANOVA (analysis of variance) was 
followed by Bonferoni’s test to determine the statistical significance of differences 
between mean values. For all statistical comparisons, p<0.05 was considered significant.  
. 
3. Results   
3.1. S1P2R mediates inhibition of PDGF-induced cell migration and Rac activation via 
G12/13 and Gq   
   S1P inhibited migration directed toward PDGF-B chain of naive VSMCs and vector 
control VSMCs (data not shown) in a transwell migration assay in a dose-dependent 
manner with complete inhibition at 0.1 μM S1P (Fig. 1A). S1P alone slightly inhibited 
random migration of VSMC. The selective S1P2 receptor antagonist JTE-01316 






to 0.1 μM S1P. On the other hand, overexpression of S1P2R in VSMCs shifted leftward 
the dose-response curve for S1P inhibition nearly by one order, compared to naive 
VSMCs. These observations indicate that S1P inhibition of cell migration is mediated 
via S1P2R. PDGF stimulated Rac (Fig. 1B), which is essential for PDGF-directed 
VSMC migration.8 S1P inhibited PDGF-induced Rac activation in a dose-dependent 
manner with complete inhibition at 0.1 μM S1P. JTE-013 totally abolished S1P 
inhibition of PDGF-induced Rac stimulation (Fig. 1C), indicating that Rac inhibition is 
also mediated via S1P2R.  
  In order to identify which member of the heterotrimeric G proteins is responsible for 
S1P2R-mediated migration inhibition, we determined the effects of specific inhibition of 
receptor-G protein coupling by adenovirus-mediated expression of the C-terminal 
peptides of heterotrimeric G protein α subunits (Gα-CTs) and pertussis toxin (PTX) 
pretreatment. The effectiveness and specificity of each Gα-CT peptide was previously 
demonstrated by us and other groups.13,17 The expression of each myc-tagged Gα-CT 
peptide in adenovirus-infected VSMCs was confirmed by Western blot analysis (Fig. 






Gαs-CT or LacZ (Fig. 2B) or PTX pretreatment (data not shown), abolished S1P 
inhibition of PDGF-directed migration. The expression of any of these Gα-CT peptides 
or PTX pretreatment in VSMCs did not affect PDGF-directed migration itself. Similarly, 
the expression of either of Gα12-CT, Gα13-CT and Gαq-CT, but not that of Gαs-CT or 
LacZ (Fig. 2C) or PTX pretreatment (data not shown), abolished S1P inhibition of 
PDGF-induced Rac activation. These observations indicate that the G12/13 and Gq classes 
are both necessary for S1P-induced inhibition of cell migration and Rac.  
 
3.2. G12/13- and Gq -coupled Rho activation mediates S1P inhibition of cell migration 
and Rac in a Rho kinase-independent manner   
   S1P stimulated Rho activity in a dose-dependent manner with maximum activation 
at 0.1 μM S1P (Fig. 3A). JTE-013 abolished S1P-induced Rho activation (Fig. 3B), 
indicating that S1P2R mediated Rho activation. The expression of either of Gα12-CT, 
Gα13-CT and Gαq-CT, but not that of Gαs-CT or LacZ (Fig. 3C) or PTX pretreatment 
(data not shown), abolished S1P-induced Rho activation, indicating that Rho 






inhibition, and Rho stimulation induced by S1P2R activation are all mediated via both 
G12/13 and Gq. 
In order to investigate the role of Rho in inhibition of Rac and migration in VSMCs, 
we examined the effects of C3 toxin treatment on S1P inhibition of Rac and migration. 
Treatment of VSMCs with C3 toxin induced the mobility shift of RhoA which reflected 
ADP ribosylation, and abolished RhoA binding to the Rho-binding domain of the Rho 
effector Rhotekin, confirming effective inactivation of cellular Rho (Fig. 4A). C3 toxin 
strongly suppressed S1P inhibition of PDGF-directed migration but did not affect 
PDGF-directed migration itself (Fig. 4B). Similarly, C3 toxin treatment nearly abolished 
S1P suppression of PDGF-induced Rac activation (Fig. 4C). Thus, S1P2R-mediated 
inhibition of PDGF-stimulated Rac activation and cell migration is dependent on Rho.  
We examined the possible involvement of a Rho kinase, a downstream effector of 
Rho, in S1P inhibition of migration and Rac, because a Rho kinase inhibitor was 
previously reported to block S1P inhibition of cell migration in other cell types.18 The 
Rho kinase inhibitor HA-1077 (fasudil) did not inhibit PDGF-directed cell migration 






S1P-induced inhibition of PDGF-directed migration at the maximal concentration but 
did not block the most part of the S1P inhibition. Consistent with these observations, 
HA-1077 failed to reverse S1P inhibition of PDGF-induced membrane ruffling (Fig. 
5B) and Rac activation (Fig. 5C). The effectiveness of HA-1077 in inhibiting Rho 
kinase in VSMCs was confirmed by the observations that this compound abolished 
S1P-induced stress fiber formatiomn (Fig. 5B) and S1P-induced stimulation of 
phosphorylation of the myosin-targeting subunit of myosin light chain phosphatase, 
MYPT1 (Fig. 5D). Similarly to the effect of HA-1077, the expression of a dominant 
negative form of Rho kinase, DN-ROCK, failed to suppress S1P-induced inhibition of 
PDGF-directed migration (Fig. 5E). The observations suggest that S1P2R-mediated 
inhibition of PDGF-stimulated Rac activation and cell migration is independent of Rho 
kinase. 
 
3.3. Gq is necessary but not sufficient for activation of Rho or inhibition of Rac and 
migration 






phospholipase C stimulation and Ca2+ mobilization via AT1R in VSMCs.19 Ang II did 
not stimulate Rho or inhibit PDGF-induced Rac activation or migration in 
vector-transfected (control) VSMCs (Figs. 6B-6D), suggesting that activation of Gq 
alone is not sufficient for Rho stimulation or resultant inhibition of Rac and migration. 
In order to explore the role of G12/13 in AT1R signaling, we established VSMCs stably 
overexpressing either wild type AT1R or the AT1-Gα12 fusion receptor (AT1-Gα12R) in 
which Gα12 is fused to AT1 at its C-terminus and, thereby, the coupling to G12 is 
facilitated (Fig. 6A), and compared their abilities to stimulate Rho and to inhibit Rac 
and migration. In AT1R-overexpressing VSMCs, Ang II tended to only slightly stimulate 
Rho, whereas Ang II induced a 1.8-fold increase in GTP-Rho in 
AT1-Gα12R-overexpressing cells (Fig. 6B). Ang II did not at all affect PDGF-induced 
Rac activation in either vector-transfected or AT1R-overexpressing VSMCs, but 
inhibited PDGF-induced Rac activation in AT1-Gα12R-overexpressing VSMCs 
approximately by 50% (Fig. 6C). Consistent with this observation, Ang II inhibited 
PDGF-directed migration in AT1-Gα12R-overexpressing VSMCs, but not in 






stimulated cell migration in vector control VSMCs. Thus, the Gq signaling pathway by 
itself seems to be insufficient for stimulating Rho, but additional activation of the G12/13 
pathway results in inhibition of Rac and cell migration with Rho stimulation. 
 
3.4. Gαq mediates Rho activation through a Ca2+- and protein kinase C-independent 
mechanism 
Gq mediates stimulation of phospholipase C (PLC), resulting in Ca2+ mobilization 
and protein kinase C activation. Previous studies20,21 suggested the involvement of Ca2+ 
and protein kinase C in Rho-induced cellular responses. We examined the involvement 
of PLC, Ca2+, and protein kinase C in S1P-induced Rho activation. The PLC inhibitor 
U73122, which totally inhibited S1P-induced increase in the intracellular free Ca2+ 
concentration ([Ca2+]i ) in VSMCs, did not affect S1P-induced Rho activation 
(supplementary Figure). The cell permeable Ca2+-chelator BAPTA-AM did not inhibit 
S1P stimulation of Rho. The protein kinase C activator phorbol-12,13-dibutyrate 
(PDBu) did not stimulate Rho (Fig. 8C). Thus, the mechanism of the Gq involvement in 









3. Discussion   
   Migration of VSMCs into the intima is a critical step that gives rise to the formation 
of atheroma and vascular stenotic lesions.1 Migration of VSMCs is positively and 
negatively regulated by chemoattractants and inhibitory mediators, respectively.22 Upon 
ligand binding, chemoattractant receptors, which include receptor tyrosine kinases, 
GPCRs and cytokine type receptors, activate complex signaling cascades involving 
protein tyrosine kinases, PI (phosphoinositide) 3-kinase, and the small G proteins, 
particularly Rho family GTPases.22 Among Rho family GTPases, Rac is activated by 
numerous chemoattractants and serves essential roles for cell migration, as well as 
Cdc42.10 Compared with chemoattractant receptors, much less is known about the 
signaling mechanisms of inhibitory or repellant receptors. Among these, we identified 
S1P2R as the first example of a GPCR that mediates negative regulation of Rac and, 






other cell types.7,9  
   We previously demonstrated in the same type of VSMCs as employed in the present 
study that the repellant receptor S1P2R is a predominantly expressed isoform whereas 
the expression levels of the attractant receptors S1P1R and S1P3R are moderate or very 
low.14 Consistent with these observations, S1P inhibited both random migration and 
PDGF-directed migration of VSMCs in a manner sensitive to the selective S1P2R 
antagonist JTE013 (Fig. 1A). We previously showed in CHO cells that S1P2R-induced 
inhibition of Rac, a molecular switch for actin reorganization and cell migration, is a 
major mechanism for S1P2R-mediated inhibition of cell migration.9 S1P inhibited 
PDGF-induced Rac activation via S1P2R in VSMCs (Fig. 1B and 2C) with a similar 
dose-response relationship as that for inhibition of cell migration (Fig. 1A), suggesting 
that S1P2R-mediated Rac inhibition is at least in part responsible for S1P inhibition of 
migration in VSMCs. 
  S1P2R couples to multiple heterotrimeric G proteins.9 We took advantage of 
adenovirus-mediated expression of specific inhibitor peptides and pertussis toxin to 






migration. The results showed that S1P2R-mediated inhibition of Rac and cell migration 
required both Gq and G12/13 in VSMCs (Figs. 2B and 2C). G12/13 is well known to 
mediate coupling of GPCR activation to Rho stimulation.20 S1P2R-mediated Rho 
activation in VSMCs was dependent on not only G12/13 but also on Gq, similarly to 
inhibition of Rac and migration (Fig. 3). We previously observed in CHO cells 
overexpressing S1P2R that S1P2R-mediated inhibition of Rac and cell migration was 
dependent on Rho.13 This was also the case in VSMCs (Fig. 4). Our previous study9 
showed that Gα13-CT is a selective inhibitor for G13 whereas Gα12-CT inhibits both G12 
and G13. In addition, either Gα12-CT or Gα13-CT does not affect the Gq coupling, and 
vice versa. Therefore, our observations suggest that all of G12, G13 and Gq are required, 
or both G13 and Gq are required for S1P-induced Rac inhibition in VSMCs. Previous 
studies20, 23 on non-muscle cells demonstrated that stimulation of GPCRs with various 
receptor agonists including lysophosphatidic acid, endothelin-1 and thrombin induced 
Rho activation through receptor coupling to the G12/13 family of the heterotrimeric G 
proteins. Direct physical and functional interaction of Gα12/13 with a group of Rho-GEFs 






domain (the RGS box), which include p115RhoGEF, PDZ-RhoGEF and LARG, was 
demonstrated.23 More recent studies20 showed that Gq also had the ability to mediate 
Rho stimulation through the similar mechanisms in certain non-muscle cell types.  
   In the present study, Gq activation by Ang II did not induce either Rho stimulation or 
inhibition of Rac or cell migration (Fig. 6) although Gαq was reported to directly 
associate with RhoGEFs in non-muscle cells.20 The observations suggest that Gq 
activation by itself is not sufficient for effective Rho activation and the following 
inhibition of Rac and migration in VSMCs. Forced coupling of AT1R to G12 by fusing 
Gα12 at the C-terminus of AT1R enabled Ang II-induced Rho activation and inhibition of 
Rac and migration. These observations, together with the finding that S1P2R-mediated 
Rho activation is dependent on both G12/13 and Gq, suggest that Gq may exert a 
permissive effect on Rho activation in cooperation with G12/13. A previous study24 
showed that the expression of activated forms of Gα12 and Gα13, but not Gαq, in 
VSMCs induced contraction that was inhibited by C3 toxin, which is also consistent 
with the notion that Gq plays a permissive role in Rho activation in VSMCs. Previous 






kinase C in Rho-dependent responses induced by expression of a constitutively active 
mutant of Gαq. However, it was unclear in these studies whether Ca2+ and protein 
kinase C affected the process of Rho activation itself or at a site(s) downstream of Rho 
activation. Our results suggest that PLC or its downstream second messengers, Ca2+ or 
protein kinase C, are likely not involved in S1P2R-mediated Rho activation 
(supplementary Fig. 1).  
   A number of downstream effectors of Rho have been identified, including Rho 
kinase, Dia, protein kinase N (PKN), rhotekin, rhophilin, citron and citron kinase.25 
Among them, Rho kinase has been well-investigated and found to be essential for 
Rho-induced formation of stress fibers and focal adhesions and Rho-induced negative 
regulation of myosin phosphatase.25 In the present study, either the Rho kinase inhibitor 
HA-1077 or the expression of a dominant negative form of Rho kinase did not suppress 
S1P2R-mediated inhibition of Rac, cell migration, or membrane ruffling although 
HA-1077 effectively inhibited S1P2R-mediated Rho-dependent stress fiber formation 
(Fig. 5). These our results indicate that a Rho effector other than Rho kinase participates 






remains to be identified. 
   Previous investigations suggested that S1P exerts both atherogenic and 
anti-atherogenic effects. S1P1R but not S1P3R was shown to suppresses adhesion of 
leukocytes onto endothelial cells in the isolated aorta,26 whereas in cultured endothelial 
cells both S1P1R and S1P3R were shown to stimulate expression of adhesion molecules 
and monocytic cell adhesion.27 In the latter investigations S1P1R also exerted inhibitory 
effects on adhesion molecule expression through PI 3-kinase and eNOS in cultured 
endothelial cells. Thus, there is still some controversy concerning the roles of S1P 
receptors in the regulation of adhesion molecule expression in endothelial cells. In 
addition, S1P1R suppresses vascular permeability28 whereas S1P2R induces vascular 
hyperpermeability.29 In vivo, the synthetic S1P analogue FTY720 inhibited development 
of atherosclerosis in murine models of hypercholesterolemia probably through 
modulating functions of lymphocytes and macrophages via S1P1R and S1P4R, both of 
which are major targets of FTY720.30 S1P1R, which is upregulated in neointimal 
VSMCs, stimulates migration of neointimal VSMCs, suggesting its stimulatory role in 






very recent report32 showed that neointima formation in vivo in the carotid artery 
ligation model is increased in S1P2R-null mice compared with wild type mice, 
indicating that S1P2R mediates an inhibitory effect on neointima formation. Thus, in 
atherosclerotic lesions and other vasoocclusive lesions, S1P appears to exert 
complicated effects on lesion formation through multiple mechanisms in receptor 
subtype- and cell type-specific manners. Selective activation of S1P2R in VSMCs by 
local drug delivery methods including a drug-eluting stent at stenotic sites could inhibit 
accumulation of VSMCs into the luminal surface by uniquely activating a 
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Figure legends       
Figure 1.  S1P inhibits PDGF-triggered chemotaxis and Rac activation via S1P2R in 
VSMCs. A, Dose-dependent inhibition of PDGF-directed migration. Transwell 
migration across the porous filter of non-transfected, VCMCs (naive) and VSMCs 
stably overexpressing S1P2R (S1P2) toward PDGF (0.41 nM) was determined in the 
presence and absence of various concentrations of S1P and JTE-013 (1 μM) in the lower 
well of the Boyden chamber. OD indicates optical density. ∗ and ∗∗ denote p<0.05 and 
p<0.01, respectively, compared with the values in the absence of S1P. B, 
Dose-dependent inhibition of PDGF-induced Rac activation by S1P. VSMCs were 
pretreated with various concentrations of S1P for 5 minutes and then stimulated with 
PDGF (0.41 nM) for 2 minutes. The cells were then subjected to a pulldown assay for 
GTP-Rac as described in Material and Methods. 1/100 of total Rac present in each 
sample is also shown to confirm loading of equal amounts of proteins (bottom). ∗ and 
∗∗ denote p<0.05 and p<0.01, respectively, compared with PDGF alone. C, Blockade of 
S1P inhibition of PDGF-induced Rac activation by the S1P2R-selective inhibitor 






treated with 0.1 μM S1P for 5 min, followed by stimulation with PDGF (0.41 nM) for 2 
minutes.  
 
Figure 2.  Effects of selective blockade of G12, G13, Gq, and Gs on S1P inhibition of 
PDGF-induced chemotaxis and Rac activation in VSMCs. A, Expression of myc-tagged 
Gα12-CT, Gα13-CT, Gαq-CT, and Gαs-CT. VSMCs were infected with indicated 
adenoviruses and analyzed for expression of each Gα-CT peptide by Western blotting 
using anti-myc antibody. B and C, Effects of Gα-CT peptides on S1P inhibition of 
PDGF-directed chemotaxis (B) and PDGF-induced Rac activation (C). VSMCs    
were infected with adenovirus encoding Gα12-CT, Gα13-CT, Gαq-CT, Gαs-CT or LacZ 
as described in Material and Methods, and then subjected to transwell migration assay 
(B). VSMCs were stimulated with PDGF (0.41nM). In (C), VSMCs were pretreated 
with 0.1 μM S1P for 5 minutes and then stimulated with PDGF (0.41 nM) for 2 minutes, 








Figure 3. Effects of selective blockade of G12, G13, Gq, and Gs on S1P-induced Rho 
activation in VSMCs. A, Dose-dependent stimulation of Rho by S1P. VSMCs were 
stimulated with various concentrations of S1P for 3 minutes and were subjected to a 
pull-down assay for GTP-Rho as described in Material and Methods. 1/100 of total Rho 
present in each sample is also shown to confirm loading of equal amounts of proteins 
(bottom).  ∗∗ denotes p<0.01 compared with no stimulation. B, Blockade of 
S1P-induced Rho activation by the S1P2R-selective inhibitor JTE-013. VSMCs were 
pretreated or not with JTE-013 (1 μM) for 10 minutes and stimulated with 0.1 μM S1P 
for 3 min. C, Effects of Gα-CT peptides on S1P-induced Rho activation. VSMCs were 
infected with adenovirus encoding Gα12-CT, Gα13-CT, Gαq-CT, Gαs-CT or LacZ as 
described in Material and Methods. VSMCs were stimulated with 0.1 μM S1P for 3 min. 
In C, ∗∗ denotes p<0.01 compared with S1P stimulation in LacZ virus-infected cells. 
 
Figure 4. S1P inhibition of PDGF-induced chemotaxis and Rac activation is dependent 
on Rho. A, ADP-ribosylation of RhoA and inhibition of binding to rhotekin by C3 






bind to GST-rhotekin beads. In B and C, VSMCs that had been pretreated or not with 
C3 toxin were subjected to transwell migration (B) and pull-down assay for Rac (C). 
VSMCs were treated with S1P and stimulated with PDGF as described in Fig. 1A and 
Fig. 2B. In B, ∗∗ denotes p<0.01 compared with PDGF stimulation in the absence of 
S1P. 
 
Figure 5. Neither a Rho kinase inhibitor nor a dominant negative form of Rho kinase 
suppresses S1P inhibition of PDGF-induced chemotaxis, lamellipodium formation, Rac 
activation or MYPT1 phosphorylation. A, VSMCs were pretreated or not with HA-1077 
(HA) (10, 30 or 50 μM) for 15 minutes before transwell migration assay. Transwell 
migration was determined in the presence or absence of PDGF (0.41 nM) and S1P (0.1 
μM) in the lower chamber. HA-1077 was present in both the upper and lower chambers, 
where indicated. B, VSMCs were pretreated or not with HA-1077 (20 μM) for 15 
minutes and then treated with S1P (0.1 μM) for 10 min when indicated. The cells were 
then stimulated with PDGF (0.41 nM) for 30 min. F-actin was visualized by staining 






pretreated or not with S1P (0.1 μM) for 5 min and stimulated with PDGF (0.41 nM) for 
2 minutes, followed by pull-down assay for GTP-Rac. HA-1077 (20 μM) was added 15 
min before the addition of S1P when indicated. D, VSMCs were pretreated with 
HA-1077 or left untreated as in C and stimulated with S1P (0.1 μM) for 3 min. The cell 
lysate was analyzed for phosphorylation at Thr850 of MYPT1 and total amount of 
MYPT1. E, VSMCs were co-transfected with LacZ-expression vector and either 
expression vector of a DN-ROCK or empty vector, and subjected to transwell migration 
assay followed by quantification of migrated cells as described in “Materials and 
Methods”.  The numbers of migrated cells in the presence of PDGF alone were 72±8 
and 152±7 cells/five low power fields in vector- and DN-ROCK-transfection, 
respectively. ∗ and ∗∗ denote p<0.05 and p<0.01, respectively, compared with the 
values in the presence of PDGF alone. 
 
Figure 6. Facilitation of AT1 receptor coupling to G12 enables stimulation of Rho and 
inhibition of Rac and migration. A, Expression of AT1R and AT1-Gα12 fusion receptor 






vectors and empty vector and selected in the presence of G418 as described in Materials 
and Methods. The mRNA levels of AT1R and AT1-Gα12R were analyzed by Northern 
analysis using AT1R cDNA. B-D, The effects of angiotensin II (Ang II) on the amounts 
of GTP-Rho (B), PDGF-induced increases in GTP-Rac (C), and PDGF-directed cell 
migration (D) were determined. VSMCs were pretreated or not with 0.1 μM Ang II for 
5 min, and stimulated with PDGF (0.41 nM) for 2 min (GTP-Rac assay) or for 3 min 
(GTP-Rho assay). The cells were then subjected to pull-down assays for GTP-Rac and 
GTP-Rho. Transwell migration of VSMCs toward PDGF (0.41 nM) was determined in 
the presence and absence of various concentrations of Ang II (0.1 μM) in the lower well 
of the Boyden chamber. In B, ∗ denotes p<0.05 compared with no stimulation. In C and 
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S1P2R-mediated Rho activation is not dependent on phospholipase C stimulation, 
calcium mobilization or protein kinase C activation. A, Effects of the PLCβ inhibitor on 
S1P-induced Rho activation. VSMCs were pretreated or not with the PLCβ inhibitor 
U73122 (10 μM) for 10 minutes followed by stimulation with S1P (0.1 μM) for 3 minutes 
and then subjected to a pulldown assay for GTP-Rho. B, Effects of the Ca2+-chelator 
BAPTA-AM on S1P-induced Rho activation. VSMC were incubated with BAPTA-AM 
(50 μM) for 30 minutes and stimulated with S1P (0.1 μM) for 3 minutes, followed by 
GTP-RhoA pulldown assay. C, Effects of a PKC activator on Rho activity. VSMCs were 
stimulated with PDBu (0.1 μM) for 8 min or with S1P (0.1 μM) for 3 min, followed by 
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